Foreign Direct Investment in laboratory and POC tests into Finland
Having been established in 2002, Orgenium celebrates its 10 years of innovations in ELISA diagnostics and its 5 years as independent business unit of Ani Biotech in 2012. Now, with a significant foreign direct investment into Finland, the financial position of Ani Biotech, the pioneering innovator and producer of home and point-of-care tests for cardiac, fertility, gastroenterology and infectious disease biomarkers for 25 years, will be clearly strengthened. The Finnish company will integrate international operations with Orgenium and Ani Labsystems, expand existing product lines and enter into new technologies, strengthen sales operations in Europe, North and Latin America, Middle East and Africa, and Asia and increase R&D capabilities aiming at bringing customers new cutting edge products, says President Mika Saramäki.

The investor Trivitron Healthcare, the largest medical technology company of Indian origin will form a strategic partnership with the companies based in Finland thus expanding their capabilities in multiple ways. The new Chennai based factory in India will enable Trivitron’s access to new infectious disease testing products for emerging markets and offer their customers new value-oriented product lines in South Asia, South East Asia, Middle East and Africa, says Dr G.S.K. Velu, founder and managing director of Trivitron. The strategic partnership will not change the existing respective distribution relationships but allows both companies to better serve their customers and provide them the products, support and training that they need in their markets. Ani Labsystems, Ani Biotech and Orgenium will continue to produce the highest quality products in the Helsinki Vantaa factory in Finland factory while Trivitron will build a new factory focused on emerging market value products in India.

Research and Development
Orgenium Laboratories has a long-standing history of cooperation with the Pulmonary Cell Research Laboratory at the University Hospital Basel, Switzerland. This collaboration with the leading experts in the pulmonary research field has further strengthened our active and dynamic participation in R&D projects. It has also enabled us to focus on and respond to the changing customer and market needs.

Quality
All our products are manufactured under strictly controlled CE and ISO 9001:2000 and 13485:2003 certified processes in our facilities in Helsinki. Our core production staff and production facilities adhere closely to the guidelines of our Quality System, ensuring conformity to consistent product quality.
By separating each key phase in our production and quality control testing into distinct self-sufficient laboratory areas we are able to ensure that each stage functions independently and reliably.

Products
Orgenium’s product range consists of ELISA tests for in vitro diagnosis of infectious diseases; ELISA Tests for quantitative detection of cytokines and growth factors as well as the new ELISA based ActiQuant Assay for the quantitative detection of DNA Binding Proteins like Glucocorticoid Receptors.

All Clinikit ELISA kits for in vitro diagnostic use are CE-marked.

Customer Service